泌尿器科領域におけるTAB(BCP)の使用経験

概要

論文の詳細を見る
Oral administration of TAB (BCP) (5-n-butyl-1-cyclohexyl-2, 4, 6-trioxoperhydropyrimidine) was attempted in 14 patients undergone urological operations and 21 patients with urogenital infections in order to study its antiedematous and antiinflammatory effects. Sinc the number of cases were inadequate to evaluate a difinite effectiveness of the drug, it is necessary to repeat the study with different dosage and duration of administration in selected cases to obtain conclusive informations on the drug. For 3 cases having normal renal functions, blood conc e ntration and urinary excretion were determined after administration of BCP at the dose of 600 mg per day, In 2 to 3 days after initiation of the drug, blood concentration reached to nearly plateau lelvel of 7 to 11 mg%. Almost complete disapperance was recognized in 4 days after cessation of administration. About 15 % to 20 % of given dose excreted as free and conjugated types of BCP.
泌尿器科紀要刊行会の論文